Fig. 6From: Role of MAML1 in targeted therapy against the esophageal cancer stem cellsMigration assay was performed in transfected and non-transfected CD44+ CSCs. The cells were monitored in 5 days intervals (×10 objective; OPTIKA, Italy)Back to article page